您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > PX-12
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PX-12
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PX-12图片
CAS NO:141400-58-0
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)188.31
FormulaC7H12N2S2
CAS No.141400-58-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 38 mg/mL (201.8 mM)
Water: <1 mg/mL
Ethanol: 38 mg/mL (201.8 mM)
Other info

Chemical Name: 2-(sec-butyldisulfanyl)-1H-imidazole.

InChi Key: BPBPYQWMFCTCNG-UHFFFAOYSA-N

InChi Code: InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)

SMILES Code: CCC(SSC1=NC=CN1)C

SynonymsPX12; PX 12; PX-12
实验参考方法
In Vitro

In vitro activity: In MCF-7 and HT-29 cells, PX-12 prevents the hypoxia (1% oxygen)-induced increase in HIF-1alpha protein, and decreases HIF-1-trans-activating activity, VEGF formation, and inducible nitric oxide synthase. PX-12 also inhibits the growth of MCF-7 and HT-29 cells with IC50s of 1.9 μM and 2.9μM, respectively. PX-12 also inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase. In A549 cells, PX-12 inhibits cell growth via G2/M phase arrest, and Bax-mediated and ROS-dependent apoptosis. In hepatocelluar carcinoma cells, PX-12 exerts a synergistic effect with 5-FU to significantly suppress tumorigenicity.


Cell Assay: Cell growth is measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells are exposed to a range of concentrations of PX-12 or pleurotin for 16 h in air or hypoxia (1% oxygen). The cells are then washed with warm drug-free medium and grown in air for the remainder of the 72-h incubation.

In VivoIn mice bearing MCF-7 tumor xenografts, PX-12 (12 mg/kg, i.p.) decreases HIF-1α and VEGF protein levels and microvessel density.
Animal modelMice bearing MCF-7 tumor xenografts
Formulation & DosageDissolved in 0.01 N HCl, polyethylene glycol-400 (2.0 mg/ml); 12 mg/kg; i.p.
References

Mol Cancer Ther. 2003 Mar;2(3):235-43; Cancer Chemother Pharmacol. 2011 Aug;68(2):405-13.